Answers are grounded in this paper and cite their sources.
BZDs remain a mainstay in the treatment of anxiety, as both monotherapy and adjunctive therapy. Factors to consider prior to prescribing a BZD include the patient's diagnosis, as well as drug characteristics, including the potential for interactions with other drugs, the risk of dependence and withdrawal, and the required frequency of dosing.
No takes yet. Share an insight, caveat, or question.
Kaplan et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: